Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 16,402,273	$ 23,895,875	$ 37,879,325
General and administrative	20,969,771	13,550,478	14,931,887
Acquired in-process research and development	76,020,184
Total operating expenses	113,392,228	37,446,353	52,811,212
Other income (expense):
Interest income (expense), net	448,667	1,648	222,652
Foreign currency gain (loss)	281,534	317,402	(890,252)
Total other income (loss)	730,201	319,050	(667,600)
Net loss	(112,662,027)	(37,127,303)	(53,478,812)
Other comprehensive loss:
Foreign currency translation	(264,452)	(321,695)	1,496,517
Total comprehensive loss	$ (112,926,479)	$ (37,448,998)	$ (51,982,295)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (67.99)	$ (34.88)	$ (50.61)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (68.16)	$ (34.88)	$ (50.61)
Weighted-average common shares outstanding, basic (in shares)	1,657,055	1,064,325	1,056,681
Weighted-average common shares outstanding, diluted (in shares)	1,657,055	1,064,325	1,056,681